Jonathan Cohen

Jonathan Cohen is President & CEO of 20/20 GeneSystems, Inc. (Rockville, MD). 20/20 develops and commercializes machine learning powered laboratory tests for the early detection of cancer and other diseases. The company saw over 600% revenue growth in FY’20 and it expects to be listed as one of the Inc. 5000 Fastest Growing Companies in America in the summer of 2021.

In Q’4 2021 the company will establish what is believed to be the country’s first shared CLIA lab accelerator for innovative developers of laboratory tests.

As a seasoned health technology entrepreneur Cohen has raised over $20 million in equity capital and forged and managed license, technology transfer, investment, and sales & marketing agreements with Fortune 500 companies such as Eastman Kodak, Abbott Diagnostics, Johnson & Johnson, and Ping An, the largest health insurance company in China.

Mr. Cohen has also been a leading advocate for the life sciences industry at the state and federal levels. He is the architect of the Maryland Biotechnology Investor Tax Credit, the most aggressive investor incentive in the U.S. Jonathan also led the legislative effort that resulted in the first increase in funding under the federal Small Business Innovative Research (SBIR) in over 30 years.

Jonathan is a registered patent attorney with an M.S. in Biotechnology from Johns Hopkins University and a J.D. from the American University.